Biosimilars and patient safety risk: promoting policy protections in the health delivery system

DOI: 10.7175/rhc.v3i2.203

Keywords: Biosimilars , Clinical risk , Patient safety , Health delivery system

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text